ArticleAsian Pacific journal of cancer prevention : APJCP2025
Evaluation of Inflammatory Biomarkers Gal-1 and IL-1β and Liver Enzyme Activities in Gastric Cancer Patients Pre- and Post-Chemotherapy: A Case-Control Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of the present study was to measure the serum levels of two inflammatory biomarkers, galectin-1 (Gal-1) and interleukin-1 beta (IL-1β), as well as liver enzyme activities, in gastric cancer (GC) patients before and after chemotherapy, and to compare these findings with healthy controls.
methodsThe study included 75 gastric cancer patients and 50 controls. Serum levels of IL-1β and Gal-1 were measured using the ELISA method, and liver enzyme activity was assessed using the kinetic chromogenic method with commercial kits.
resultsBaseline levels of Gal-1 and IL-1β were significantly higher in patients compared to controls (38.1 ng/ml vs 16.1 ng/ml; p <0.001 for Gal-1, 86.3 pg/mL vs 18.8 pg/mL; p <0,001 for IL-1β). And also Baseline levels of ALT, AST and ALP was significantly higher in the patient group pages Following chemotherapy, levels of IL-1β significantly decreased to 67.9 pg/ml (P < 0.001) and Gal-1 showed a modest decrease to 37.2 ng/ml (not significant, P = 0.06). Although reduced by about 10%, both biomarkers remained significantly higher compared to controls (P < 0.001). In contrast, the activities of liver enzymes significantly increased after chemotherapy.
conclusionBoth Gal-1 and IL-1β play pivotal roles in causing inflammation during the development of GC, and their expression may represent an integrated systemic inflammatory process in GC patients regardless of gastrectomy as well as chemotherapy. In addition, the combination chemotherapy in treatment of GC led to hepatotoxicity as suggested by sera hepatic enzyme activities during and following therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.